Scholars@Duke publication: No association of alpha1-antichymotrypsin flanking region polymorphism and Alzheimer disease risk in early- and late-onset Alzheimer disease patients.

No association of alpha1-antichymotrypsin flanking region polymorphism and Alzheimer disease risk in early- and late-onset Alzheimer disease patients.

Publication , Journal Article

Bass, MP; Yamaoka, LH; Scott, WK; Gaskell, PC; Welsh-Bohmer, KA; Roses, AD; Saunders, AM; Haines, JL; Pericak-Vance, MA

Published in: Neurosci Lett

July 3, 1998

The alpha1-antichymotrypsin (AACT)-155 allele was found elsewhere to have a significant effect on Alzheimer disease (AD) risk in individuals with at least one APOE-4 allele. We compared AACT genotypes of 284 cases of sporadic AD and 172 controls. The frequency of the AACT-155 allele did not differ significantly between cases and controls, either overall or when restricted to subjects with at least one APOE-4 allele. Logistic regression controlling for age and sex failed to show an effect due to AACT either alone or acting with APOE. There was no evidence of an interaction between APOE-4 and the AACT-155 allele to reduce age at onset. Thus, our data do not support an association of AACT-155 with risk or age at onset in AD.

Duke Scholars

Author Kathleen Anne Welsh-Bohmer Psychiatry & Behavioral Sciences, Behavioral Medicine & Neur ...

Author Margaret Ann Pericak-Vance Medicine, Hematology

Published In

Neurosci Lett

DOI

10.1016/s0304-3940(98)00398-x

ISSN

0304-3940

Publication Date

July 3, 1998

Volume

250

Issue

Start / End Page

79 / 82

Location

Ireland

Related Subject Headings

alpha 1-Antichymotrypsin
Risk Factors
Polymorphism, Genetic
Middle Aged
Male
Humans
Genotype
Female
Alzheimer Disease
Alleles

Citation

APA

Chicago

ICMJE

MLA

NLM

Bass, M. P., Yamaoka, L. H., Scott, W. K., Gaskell, P. C., Welsh-Bohmer, K. A., Roses, A. D., … Pericak-Vance, M. A. (1998). No association of alpha1-antichymotrypsin flanking region polymorphism and Alzheimer disease risk in early- and late-onset Alzheimer disease patients. Neurosci Lett, 250(2), 79–82. https://doi.org/10.1016/s0304-3940(98)00398-x

Bass, M. P., L. H. Yamaoka, W. K. Scott, P. C. Gaskell, K. A. Welsh-Bohmer, A. D. Roses, A. M. Saunders, J. L. Haines, and M. A. Pericak-Vance. “No association of alpha1-antichymotrypsin flanking region polymorphism and Alzheimer disease risk in early- and late-onset Alzheimer disease patients.” Neurosci Lett 250, no. 2 (July 3, 1998): 79–82. https://doi.org/10.1016/s0304-3940(98)00398-x.

Bass MP, Yamaoka LH, Scott WK, Gaskell PC, Welsh-Bohmer KA, Roses AD, et al. No association of alpha1-antichymotrypsin flanking region polymorphism and Alzheimer disease risk in early- and late-onset Alzheimer disease patients. Neurosci Lett. 1998 Jul 3;250(2):79–82.

Bass, M. P., et al. “No association of alpha1-antichymotrypsin flanking region polymorphism and Alzheimer disease risk in early- and late-onset Alzheimer disease patients.” Neurosci Lett, vol. 250, no. 2, July 1998, pp. 79–82. Pubmed, doi:10.1016/s0304-3940(98)00398-x.

Bass MP, Yamaoka LH, Scott WK, Gaskell PC, Welsh-Bohmer KA, Roses AD, Saunders AM, Haines JL, Pericak-Vance MA. No association of alpha1-antichymotrypsin flanking region polymorphism and Alzheimer disease risk in early- and late-onset Alzheimer disease patients. Neurosci Lett. 1998 Jul 3;250(2):79–82.